# Data Sheet (Cat.No.TMPK-00166)

TargetMol

## PD-L2 Protein, Human, Recombinant (His & Avi)

### General Information

| | |
|---|---|
| Synonyms: | PDL2;Btdc;Butyrophilin B7-DC;PDCD1LG2;bA574F11.2;CD273, PDCD1 ligand 2;B7DC;PD-L2; PDCD1L2 |
| Protein Construction: | Leu20-Thr220 |
| Species: | Human |
| Expression Host: | HEK293 Cells |
| Accession: | Q9BQ51 |
| Molecular Weight: | 25.3 kDa (predicted). Due to glycosylation, the protein migrates to 40-52 kDa based on Tris-Bis PAGE result. |

### QC Testing

| | |
|---|---|
| Biological Activity: | Human PD-1, hFc Tag captured on CM5 Chip via Protein A can bind Human PD-L2, His Tag with an affinity constant of 0.296 μM as determined in SPR assay. |
| Purity: | > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
| Endotoxin: | < 1.0 EU/μg of the protein as determined by the LAL method. |
| Formulation: | Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS (pH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization. |

### Preparation and Storage

Reconstitution:

Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.

Stability & Storage:

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

Shipping:

In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

### Protein Background

PD-1 ligand 2 (PD-L2) as a second ligand for PD-1 and compare the function and expression of PD-L1 and PD-L2. Engagement of PD-1 by PD-L2 dramatically inhibits T cell receptor (TCR)-mediated proliferation and cytokine production by CD4 T cells. At low antigen concentrations, PD-L2-PD-1 interactions inhibit strong B7-CD28 signals.

Reference

Yearley JH, et al. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer. Clin Cancer Res. 2017;23(12):3158-3167. doi:10.1158/1078-0432.CCR-16-1761



Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481